TransCode Therapeutics Inc (NASDAQ:RNAZ) currently has a daily average trading volume of 2.14M but it saw 1057488 shares traded in last market. With a market cap of 11.73M USD, the company’s current market price of $0.68 came falling about -8.11 while comparing to the previous closing price of $0.74. In past 52 weeks, the stock remained buoying in the range of price level as high as $21.20 and as low as $0.22. In the recent trading on the day, stock has struck highest price mark of $0.6616 while lowest mark touched by it was $0.7464.
Taking a look at 20-day trading activity of TransCode Therapeutics Inc (RNAZ) gives us an average price of $0.5612, while its current price level is -96.80% below from 52-week high level whereas it is 214.40% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $0.3841 while that of 200 days or SMA-200 reads an average of $0.9410. A closer look into the stock’s movement over the week reveals that its volatility is standing at 20.74% during that period while stretching the period over a month that increases to 27.85%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 60.77 which implies that the stock is in neutral territory.
Over the week, RNAZ’s stock price is moving 25.55% up while it is 134.17% when we observe its performance for the past one month. Year-to-date it is -89.70% down and over the past year, the stock is showing a downside performance of -96.29%.
The latest quarterly earnings report issued by the company reported quarterly earnings per share (EPS) of -67.2 beaten by the consensus estimate of -60 for the same. The company is expected to be releasing its next quarterly report in November, for which analysts forecasted an EPS of -0.49 while estimate for next year EPS is -2.06. In next quarter, company is expected to be making quarterly sales of $300k as analysts are expecting the sales for current fiscal year at $500k and seeing the company making $1M in sales next year. Moreover, analysts are in estimates of $300k for current-quarter revenue.
Currently, TransCode Therapeutics Inc’s total number of outstanding shares is 17.27M. Company’s return on investment (ROI) stands at -1354.12% and return on equity (ROE) at -1048.70%. Stock’s beta reads 0.63. Stock has a price to book (P/B) ratio of 3.73. Its return on asset (ROA) is -334.48% on average.
